Wieding J U, Neumeyer H
Abteilung für Transfusionsmedizin, Universitätskliniken Göttingen.
Infusionsther Transfusionsmed. 1992 Apr;19(2):84-90.
Methylene blue (MB) has recently been introduced to inactivate viruses in single donor fresh frozen plasma (FFP) units. In the first clinical study 519 units of MB-treated FFP were given to 103 patients. No specific clinical side effects with adverse reactions were recorded. However, after thawing, clots were observed in 9 of the first 110 units, although the medical staff had thawed the MB-FFP in exactly the same manner as the conventional FFP in which clots are extremely rare. The possible effects of methylene blue were investigated by subsequent in vitro experiments: Methylene blue together with light led to generation of fibrin(ogen) derivatives which have an increased tendency for aggregation but cannot be normally clotted by thrombin and even seem to interfere with normal fibrin polymerization. Inadequate conditions during plasma preparation such as long illumination or temperatures above 40 degrees C enhanced the generation of these fibrin(ogen)-derivatives. In addition, special requirements for producers and users of MB-FFP and further investigations are necessary in order to prevent complications.
亚甲蓝（MB）最近被用于使单采新鲜冰冻血浆（FFP）单位中的病毒失活。在第一项临床研究中，103名患者接受了519单位经MB处理的FFP。未记录到有不良反应的特定临床副作用。然而，解冻后，在前110个单位中有9个出现了凝块，尽管医护人员解冻MB-FFP的方式与传统FFP完全相同，而传统FFP中极少出现凝块。随后的体外实验研究了亚甲蓝的可能影响：亚甲蓝与光共同作用导致纤维蛋白（原）衍生物的生成，这些衍生物具有增加的聚集倾向，但不能被凝血酶正常凝结，甚至似乎会干扰正常的纤维蛋白聚合。血浆制备过程中的不适当条件，如长时间光照或温度高于40摄氏度，会增强这些纤维蛋白（原）衍生物的生成。此外，为防止并发症，对MB-FFP的生产商和使用者有特殊要求，并且需要进一步研究。
